News | Stents | January 25, 2018

Elixir Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery

Elixir reveals new category of ‘Bioadaptive Drug Eluting Stents’ (BA- DES), sharing DynamX technology, preclinical data, and clinical program at 29th Transcatheter Cardiovascular Therapeutics Conference


Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery

January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling technologies designed to mimic the normal arterial function after cardiovascular and peripheral vascular disease intervention, unveiled for the first time its novel stent technology, DynamXTM, a bioadaptive drug-eluting stent (BA-DES) platform at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Denver.

DynamX, a 71 microns thin cobalt-chromium DES coated with a thin, biodegradable polymer coating that releases Novolimus, an anti-proliferative and anti-inflammatory, is the first of its kind in its ability to allow the vessel to resume arterial pulsatile motion and the Glagovian phenomenon of adaptive remodeling which are both essential for slowing disease progression and minimizing clinical events. Adaptive segments in the stent are held intact by the thin biodegradable polymer coating designed to absorb in six months allowing the adaptive segments to uncage the stent and restore the natural pulsatile motion and adaptive remodeling of the artery.

Current DES permanently cages the artery, causing geometric distortion and stresses that contribute to fractures in approximately 20 percent of stents implanted leading to clinical events. DynamX demonstrated significantly improved conformability, and reduced torsional and longitudinal stresses compared to current DES, thereby reducing geometric distortion of arteries and the potential for stent fractures and clinical events.

“The acute performance of DynamX matched the best in class DES,” said Professor Stefan Verheye, M.D., Ph.D., Antwerp, Belgium.

“I am very excited about the potential of DynamX leading PCI to the next frontier,” said Verheye.

Verheye presented DynamX’s clinical program overview at the TCT conference and was joined by a distinguished panel of faculty Co-Chairs: Martin Leon, Dean Kereiakes and Roxana Mehran.

In addition to launching a new genre of bioadaptive drug-eluting stents with DynamX, Elixir also continues to make advances with its bioresorbable scaffold programs, DESolve CX and DESolve NXT. DESolve’s ability to degrade in six months and nearly completely resorb in one year, while demonstrating positive adaptive remodeling at six-month follow-up have all been affirmations of their respective proprietary technologies and the promising future of the category.

“Elixir is committed to lead the industry to a new and exciting era with its bio-adaptive DynamX DES,” said Motasim Sirhan, CEO of Elixir Medical Corporation. “Elixir is executing on a two-pronged strategy with BRS and BA-DES to develop innovative, adaptive remodeling technologies designed to restore the normal function of arteries.”

For more information:

Related Content

Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Figure 1. Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Feature | Cath Lab | April 16, 2018 | Azeem Latib, M.D.
Over the last decade, there have been considerable developments in procedural techniques and technology facilitating
Overlay Init